Thu, Jun 20 · 8:00

IO Combinations 360° provides the most up-to-date research, data and progress on combination developments to help IO stakeholders:

- Be at the forefront of the most relevant research and developments for IO combinations from key leadership who are at the pulse of cancer immunotherapy
- Foster collaboration amongst others working in all aspects of cancer immunotherapy by rounding up all stakeholders under one roof
- Receive the latest pre-clinical, translational and clinical data from academia and industry
- Better understand what assets are available for potential combinations that may be able to give patients more treatment options
- Create and prioritize combination strategies targeted toward specific tumor types
- Get key investor and analyst evaluations and insights on the IO combination landscape
- Learn about biomarker advancements, neoantigen approaches and more
- Obtain coverage on a wide range of emerging technologies

Key topics for 2019 include:

- Discovery / Preclinical Science
- Bispecifics
- Translational Science and Biomarkers
- Next Generation Cell Therapy
- Clinical Developments
- Operationalizing Combinations
- Business Aspects
- Emerging Technologies

URLs:

Website https://go.evvnt.com/398369-0?pid=5731

Brochure https://go.evvnt.com/398369-3?pid=5731

Prices:
Pharma and Biotech standard rate: USD 1795.0
Standard Industry standard rate: USD 1795.0
Academia, Non-Profit and Government standard rate: USD 897.5

Speakers: Jon Armstrong, Julie Bailis, PhD, Roy Baynes, MD, PhD, Justine Cohen, DO, Asthika Goonewardene, Omid Hamid, MD, Christopher Heery, MD, Darren Hodgson, PhD, Axel Hoos, MD, PhD, Joanna Horobin, MB, ChB, Mahrukh Huseni, Michael Kalos, PhD, Bruce Levine, PhD, Ian McCaffery, PhD, Erin Newburn, PhD, Cokey Nguyen, PhD, Laureen Ojalvo, MD, PhD, Willem Overwijk, PhD, Drew Pardoll, MD, PhD, Mark Paris, PhD, Katy Rezvani, MD, PhD, Carlo Rizzuto, PhD, Will Singleterry, PhD, Danny Wells, PhD